We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) (MISSILE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01101802
Recruitment Status : Completed
First Posted : April 12, 2010
Last Update Posted : September 28, 2011
Sponsor:
Collaborator:
Institute of Child Health, University College London, London, UK.
Information provided by:
Guy's and St Thomas' NHS Foundation Trust

Brief Summary:
Systemic lupus erythematosus (SLE) is an independent risk factor for atherosclerosis. Endothelial dysfunction is the earliest marker of atherosclerosis and is measured by flow mediated dilation (FMD) of the brachial artery. The purpose of the study was to measure FMD in mild, stable SLE patients and look for change in FMD with the immunosuppressant drug mycophenolate mofetil (MMF).

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Atherosclerosis Drug: Mycophenolate mofetil Drug: sugar pill Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE.
Study Start Date : March 2006
Primary Completion Date : March 2008
Study Completion Date : October 2008


Arm Intervention/treatment
Active Comparator: Mycophenolate mofetil
Patients were given 1gm bd mycophenolate mofetil for 8 weeks
Drug: Mycophenolate mofetil
Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
Other Name: Cellcept
Placebo Comparator: Sugar pill Drug: sugar pill
Arm 2 patients were given 2 sugar pills bd for 8 weeks



Primary Outcome Measures :
  1. Flow mediated dilation [ Time Frame: 8 weeks ]
    Measure of endothelial function using doppler ultrasound to measure brachial artery dilation in response to increase blood flow.


Secondary Outcome Measures :
  1. BILAG, SLEDAI, [ Time Frame: 8 weeks ]
    Measurements of disease activity in SLE



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female SLE patients
  • Age 18-60 years
  • If premenopausal using a reliable method of contraception
  • Clinically stable disease
  • Taking hydroxychloroquine and up to 15mgs of prednisolone daily

Exclusion Criteria:

  • Smokers
  • Pregnancy or breast feeding
  • Use of other immunosuppressants (hydroxychloroquine and stable dose of prednisolone up to 15 mgs daily will be permitted)
  • Use of any investigational drug within 1 month prior to screening
  • Acute infections 2 weeks prior to Visit 1
  • History of ischaemic heart disease or end stage renal disease
  • Current signs or symptoms of severe, progressive or uncontrolled hepatic, haematological, gastroenterological, endocrine, pulmonary, cardiac or neurological disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01101802


Locations
United Kingdom
Lupus Research Unit, St Thomas' Hospital
London, United Kingdom, SE1 7EH
Sponsors and Collaborators
Guy's and St Thomas' NHS Foundation Trust
Institute of Child Health, University College London, London, UK.
Investigators
Principal Investigator: David P D'Cruz, MD, FRCP Guys and St Thomas' NHS Foundation Trust

Responsible Party: Dr David D'Cruz, Lupus Research Unit, St Thomas' hospital
ClinicalTrials.gov Identifier: NCT01101802     History of Changes
Other Study ID Numbers: WX18694
ISRCTN
First Posted: April 12, 2010    Key Record Dates
Last Update Posted: September 28, 2011
Last Verified: May 2005

Keywords provided by Guy's and St Thomas' NHS Foundation Trust:
SLE
Atherosclerosis
Endothelial function
Mycophenolate mofetil

Additional relevant MeSH terms:
Atherosclerosis
Lupus Erythematosus, Systemic
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Mycophenolic Acid
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action